CLINUVEL has filed its second pharmaceutical product, NEURACTHEL® Instant (tetracosactide), with European national regulators through the decentralised procedure. The filing represents a significant step forward for the company as it seeks to expand its therapeutic portfolio beyond its lead product SCENESSE®. If approved, CLINUVEL will be able to commercialise the drug across up to three initial EU member states, with potential expansion to additional markets.
NEURACTHEL® Instant is a branded generic formulation of tetracosactide, a synthetic 24-amino acid peptide analogue of adrenocorticotropic hormone (ACTH). ACTH products treat 19 conditions in the United States, including infantile spasms and acute multiple sclerosis exacerbations. In Europe, these products serve dual purposes as both therapeutic and diagnostic tools for adrenal insufficiency and related conditions. The global ACTH market is estimated at US$1.3 billion annually, presenting a substantial revenue opportunity if the company’s product gains regulatory approval and successfully commercialises across its target markets.
The company has identified three key EU member states as launch markets based on prescriber demand, pricing infrastructure, and reported drug shortages in those jurisdictions. Management has also considered overlap with CLINUVEL’s existing SCENESSE® distribution channels, allowing the company to leverage current commercial infrastructure and existing relationships. This strategic approach suggests management believes it can efficiently capture market share while potentially expanding to additional countries as regulatory approvals progress and commercial viability warrants further investment.
The European decentralised procedure typically requires 300 days of review, though timelines can extend through clock stop periods when regulators seek additional information. The final regulatory decision is expected around day 270. Management expects validation and initial feedback in approximately four months, which will provide an early indication of regulatory reception and approval likelihood. Beyond Europe, the company is evaluating further submissions to the UK’s medicines regulator and other EU member states, while US FDA filing timelines are under review. Success in Europe would validate the company’s branded generic strategy and potentially unlock access to additional markets.
A rules-based approach to leveraged ETFs
See how our quantitative strategy works and who it suits.
Explore the strategyBecome an authorised representative
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CARKey milestones to monitor include validation of the European dossier and formal regulatory feedback expected within four months. The outcome of these filings will determine whether CLINUVEL can access a market opportunity exceeding US$1 billion in annual sales and generate a meaningful second revenue stream beyond SCENESSE®. Investors should track announcements regarding UK regulatory submissions, any updates on US FDA filing timelines, and comments from management regarding commercial progress in the three initial launch markets. This announcement is price sensitive and flagged as material by the ASX.
View the full ASX announcement (PDF)
About Clinuvel Pharmaceuticals Limited (ASX: CUV)
Clinuvel Pharmaceuticals Limited is an Australian specialty pharmaceutical company headquartered in Melbourne that develops and commercializes treatments for genetic, metabolic, systemic, and life-threatening disorders. Its lead product, SCENESSE (afamelanotide 16mg), is approved for preventing phototoxicity in patients with erythropoietic protoporphyria and is available in Europe, the United States, Israel, and Australia. The company maintains a pipeline of additional therapies targeting neurological and degenerative disorders.
Become an authorised representative
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CAR